{"id":1332,"date":"2024-10-16T06:56:16","date_gmt":"2024-10-16T04:56:16","guid":{"rendered":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-hympavzi-pour-lhemophilie\/"},"modified":"2024-10-16T06:56:18","modified_gmt":"2024-10-16T04:56:18","slug":"la-fda-approuve-hympavzi-pour-lhemophilie","status":"publish","type":"post","link":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-hympavzi-pour-lhemophilie\/","title":{"rendered":"La FDA approuve Hympavzi pour l&rsquo;h\u00e9mophilie"},"content":{"rendered":"<div>\n<div class=\"article-gallery lightGallery\">\n<div data-thumb=\"https:\/\/scx1.b-cdn.net\/csz\/news\/tmb\/2024\/fda-approves-hympavzi.jpg\" data-src=\"https:\/\/scx2.b-cdn.net\/gfx\/news\/2024\/fda-approves-hympavzi.jpg\" data-sub-html=\"\">\n<figure class=\"article-img\">\n<\/figure><\/div>\n<\/div>\n<p>La Food and Drug Administration (FDA) des \u00c9tats-Unis a approuv\u00e9 Hympavzi (marstacimab-hncq) pour la prophylaxie de routine visant \u00e0 pr\u00e9venir ou \u00e0 r\u00e9duire la fr\u00e9quence des \u00e9pisodes h\u00e9morragiques chez les patients adultes et p\u00e9diatriques \u00e2g\u00e9s de 12 ans et plus atteints d&rsquo;h\u00e9mophilie A sans inhibiteurs du facteur VIII ou d&rsquo;h\u00e9mophilie B sans facteur. Inhibiteurs du IX.<\/p>\n<p>Contrairement \u00e0 d&rsquo;autres m\u00e9dicaments qui remplacent un facteur de coagulation, Hympavzi est un nouveau type de m\u00e9dicament qui agit en r\u00e9duisant la quantit\u00e9 de prot\u00e9ine anticoagulante naturelle appel\u00e9e inhibiteur de la voie du facteur tissulaire, augmentant ainsi la quantit\u00e9 de thrombine, une enzyme essentielle \u00e0 la coagulation sanguine.<\/p>\n<p>L&rsquo;approbation est bas\u00e9e sur une \u00e9tude multicentrique ouverte portant sur 116 patients adultes et p\u00e9diatriques de sexe masculin atteints d&rsquo;h\u00e9mophilie A s\u00e9v\u00e8re ou d&rsquo;h\u00e9mophilie B s\u00e9v\u00e8re, toutes deux sans inhibiteurs. Pendant les six premiers mois, les patients ont re\u00e7u un traitement par facteur de remplacement soit \u00e0 la demande (33 patients) soit \u00e0 titre prophylactique (83 patients), suivi d&rsquo;une prophylaxie Hympavzi pendant 12 mois. Chez les patients recevant un facteur de remplacement \u00e0 la demande, le taux de saignement annualis\u00e9 estim\u00e9 \u00e9tait de 38 contre 3,2 avec Hympavzi. Au cours des six premiers mois, les patients ayant re\u00e7u un facteur prophylactique de remplacement avaient un taux de saignement annualis\u00e9 estim\u00e9 \u00e0 7,85, suivi de 5,08 au cours des 12 mois suivants sous prophylaxie Hympavzi.<\/p>\n<p>\u00ab\u00a0L&rsquo;approbation d&rsquo;Hympavzi aujourd&rsquo;hui offre aux patients h\u00e9mophiles une nouvelle option de traitement qui est la premi\u00e8re du genre \u00e0 fonctionner en ciblant une prot\u00e9ine dans le processus de coagulation sanguine\u00a0\u00bb, a d\u00e9clar\u00e9 Ann Farrell, MD, du Centre d&rsquo;\u00e9valuation et de recherche des m\u00e9dicaments de la FDA. une d\u00e9claration. \u00ab Ce nouveau type de traitement souligne l&rsquo;engagement de la FDA \u00e0 faire progresser le d\u00e9veloppement de th\u00e9rapies innovantes, s\u00fbres et efficaces.<\/p>\n<p>                                        <!-- print only --><\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>La Food and Drug Administration (FDA) des \u00c9tats-Unis a approuv\u00e9 Hympavzi (marstacimab-hncq) pour la prophylaxie<\/p>\n","protected":false},"author":1,"featured_media":1333,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[86],"tags":[321,447,1686,1687,8],"class_list":["post-1332","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-les-maladies","tag-approuve","tag-fda","tag-hympavzi","tag-lhemophilie","tag-pour","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-50","resize-featured-image"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>La FDA approuve Hympavzi pour l&#039;h\u00e9mophilie - RVH-Synergie.org<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-hympavzi-pour-lhemophilie\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La FDA approuve Hympavzi pour l&#039;h\u00e9mophilie - RVH-Synergie.org\" \/>\n<meta property=\"og:description\" content=\"La Food and Drug Administration (FDA) des \u00c9tats-Unis a approuv\u00e9 Hympavzi (marstacimab-hncq) pour la prophylaxie\" \/>\n<meta property=\"og:url\" content=\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-hympavzi-pour-lhemophilie\/\" \/>\n<meta property=\"og:site_name\" content=\"RVH-Synergie\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-16T04:56:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-16T04:56:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/10\/1729054576_La-FDA-approuve-Hympavzi-pour-lhemophilie.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Charles Martinez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Charles Martinez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-hympavzi-pour-lhemophilie\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-hympavzi-pour-lhemophilie\/\"},\"author\":{\"name\":\"Charles Martinez\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560\"},\"headline\":\"La FDA approuve Hympavzi pour l&rsquo;h\u00e9mophilie\",\"datePublished\":\"2024-10-16T04:56:16+00:00\",\"dateModified\":\"2024-10-16T04:56:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-hympavzi-pour-lhemophilie\/\"},\"wordCount\":329,\"publisher\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-hympavzi-pour-lhemophilie\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/10\/1729054576_La-FDA-approuve-Hympavzi-pour-lhemophilie.jpg\",\"keywords\":[\"approuve\",\"FDA\",\"Hympavzi\",\"lh\u00e9mophilie\",\"pour\"],\"articleSection\":[\"Les maladies\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-hympavzi-pour-lhemophilie\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-hympavzi-pour-lhemophilie\/\",\"name\":\"La FDA approuve Hympavzi pour l'h\u00e9mophilie - RVH-Synergie.org\",\"isPartOf\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-hympavzi-pour-lhemophilie\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-hympavzi-pour-lhemophilie\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/10\/1729054576_La-FDA-approuve-Hympavzi-pour-lhemophilie.jpg\",\"datePublished\":\"2024-10-16T04:56:16+00:00\",\"dateModified\":\"2024-10-16T04:56:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-hympavzi-pour-lhemophilie\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-hympavzi-pour-lhemophilie\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-hympavzi-pour-lhemophilie\/#primaryimage\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/10\/1729054576_La-FDA-approuve-Hympavzi-pour-lhemophilie.jpg\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/10\/1729054576_La-FDA-approuve-Hympavzi-pour-lhemophilie.jpg\",\"width\":1280,\"height\":853,\"caption\":\"La FDA approuve Hympavzi pour l'h\u00e9mophilie\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-hympavzi-pour-lhemophilie\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/rvh-synergie.org\/actualites\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La FDA approuve Hympavzi pour l&rsquo;h\u00e9mophilie\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#website\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/\",\"name\":\"RVH-Synergie.org\",\"description\":\"RVH-Synergie, site ind\u00e9pendant d&#039;informations sur la prise en charge des addictions.\",\"publisher\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/rvh-synergie.org\/actualites\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\",\"name\":\"RVH-Synergie.org\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png\",\"width\":512,\"height\":512,\"caption\":\"RVH-Synergie.org\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560\",\"name\":\"Charles Martinez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg\",\"caption\":\"Charles Martinez\"},\"description\":\"Bonjour, je m'appelle Charles Martinez, r\u00e9dacteur passionn\u00e9 pour le m\u00e9dia RVH-synergie.org, d\u00e9di\u00e9 aux addictions et aux maladies. Depuis plus de dix ans, j'explore et rapporte les histoires poignantes des individus confront\u00e9s \u00e0 ces d\u00e9fis, tout en sensibilisant le public aux traitements novateurs et aux progr\u00e8s scientifiques dans ce domaine. Mon engagement r\u00e9side dans l'espoir de cr\u00e9er une communaut\u00e9 inform\u00e9e et empathique, pr\u00eate \u00e0 soutenir ceux qui luttent contre ces \u00e9preuves.\",\"sameAs\":[\"https:\/\/rvh-synergie.org\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La FDA approuve Hympavzi pour l'h\u00e9mophilie - RVH-Synergie.org","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-hympavzi-pour-lhemophilie\/","og_locale":"fr_FR","og_type":"article","og_title":"La FDA approuve Hympavzi pour l'h\u00e9mophilie - RVH-Synergie.org","og_description":"La Food and Drug Administration (FDA) des \u00c9tats-Unis a approuv\u00e9 Hympavzi (marstacimab-hncq) pour la prophylaxie","og_url":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-hympavzi-pour-lhemophilie\/","og_site_name":"RVH-Synergie","article_published_time":"2024-10-16T04:56:16+00:00","article_modified_time":"2024-10-16T04:56:18+00:00","og_image":[{"width":1280,"height":853,"url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/10\/1729054576_La-FDA-approuve-Hympavzi-pour-lhemophilie.jpg","type":"image\/jpeg"}],"author":"Charles Martinez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Charles Martinez","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-hympavzi-pour-lhemophilie\/#article","isPartOf":{"@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-hympavzi-pour-lhemophilie\/"},"author":{"name":"Charles Martinez","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560"},"headline":"La FDA approuve Hympavzi pour l&rsquo;h\u00e9mophilie","datePublished":"2024-10-16T04:56:16+00:00","dateModified":"2024-10-16T04:56:18+00:00","mainEntityOfPage":{"@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-hympavzi-pour-lhemophilie\/"},"wordCount":329,"publisher":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#organization"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-hympavzi-pour-lhemophilie\/#primaryimage"},"thumbnailUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/10\/1729054576_La-FDA-approuve-Hympavzi-pour-lhemophilie.jpg","keywords":["approuve","FDA","Hympavzi","lh\u00e9mophilie","pour"],"articleSection":["Les maladies"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-hympavzi-pour-lhemophilie\/","url":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-hympavzi-pour-lhemophilie\/","name":"La FDA approuve Hympavzi pour l'h\u00e9mophilie - RVH-Synergie.org","isPartOf":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#website"},"primaryImageOfPage":{"@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-hympavzi-pour-lhemophilie\/#primaryimage"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-hympavzi-pour-lhemophilie\/#primaryimage"},"thumbnailUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/10\/1729054576_La-FDA-approuve-Hympavzi-pour-lhemophilie.jpg","datePublished":"2024-10-16T04:56:16+00:00","dateModified":"2024-10-16T04:56:18+00:00","breadcrumb":{"@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-hympavzi-pour-lhemophilie\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-hympavzi-pour-lhemophilie\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-hympavzi-pour-lhemophilie\/#primaryimage","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/10\/1729054576_La-FDA-approuve-Hympavzi-pour-lhemophilie.jpg","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/10\/1729054576_La-FDA-approuve-Hympavzi-pour-lhemophilie.jpg","width":1280,"height":853,"caption":"La FDA approuve Hympavzi pour l'h\u00e9mophilie"},{"@type":"BreadcrumbList","@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-hympavzi-pour-lhemophilie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/rvh-synergie.org\/actualites\/"},{"@type":"ListItem","position":2,"name":"La FDA approuve Hympavzi pour l&rsquo;h\u00e9mophilie"}]},{"@type":"WebSite","@id":"https:\/\/rvh-synergie.org\/actualites\/#website","url":"https:\/\/rvh-synergie.org\/actualites\/","name":"RVH-Synergie.org","description":"RVH-Synergie, site ind\u00e9pendant d&#039;informations sur la prise en charge des addictions.","publisher":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/rvh-synergie.org\/actualites\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/rvh-synergie.org\/actualites\/#organization","name":"RVH-Synergie.org","url":"https:\/\/rvh-synergie.org\/actualites\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png","width":512,"height":512,"caption":"RVH-Synergie.org"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560","name":"Charles Martinez","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/image\/","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg","caption":"Charles Martinez"},"description":"Bonjour, je m'appelle Charles Martinez, r\u00e9dacteur passionn\u00e9 pour le m\u00e9dia RVH-synergie.org, d\u00e9di\u00e9 aux addictions et aux maladies. Depuis plus de dix ans, j'explore et rapporte les histoires poignantes des individus confront\u00e9s \u00e0 ces d\u00e9fis, tout en sensibilisant le public aux traitements novateurs et aux progr\u00e8s scientifiques dans ce domaine. Mon engagement r\u00e9side dans l'espoir de cr\u00e9er une communaut\u00e9 inform\u00e9e et empathique, pr\u00eate \u00e0 soutenir ceux qui luttent contre ces \u00e9preuves.","sameAs":["https:\/\/rvh-synergie.org\/"]}]}},"_links":{"self":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts\/1332","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/comments?post=1332"}],"version-history":[{"count":0,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts\/1332\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/media\/1333"}],"wp:attachment":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/media?parent=1332"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/categories?post=1332"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/tags?post=1332"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}